Neurology: Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study
Neurology: Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study is organized by American Academy of Neurology (AAN).
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of the article by Murata et al, the participant should be able to:
• Briefly discuss the possible antiparkinsonian mechanism of action of zonisamide
• Describe the effect of zonisamide on motor function, cognitive function, caregiver burden, and behavioral and psychological symptoms in this study
• Discuss the rate of adverse effects in patients receiving zonisamide vs placebo in this study
Additional details will be posted as soon as they are available.
- CME : 0.75
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine
Number of Health Care Professionals Registered: 0 Number
Toll free Number
Browse CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine